Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma
Information source: Dana-Farber Cancer Institute
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Mesothelioma
Intervention: Erlotinib (Drug); Bevacizumab (Drug)
Phase: Phase 2
Sponsored by: Dana-Farber Cancer Institute
Official(s) and/or principal investigator(s):
Pasi A Janne, MD, PhD, Principal Investigator, Affiliation: Dana-Farber Cancer Institute
The purpose of this study is to determine whether the combination of the investigational
drugs Avastin and Tarceva are effective in patients with mesothelioma who have previously
been treated with chemotherapy.
Official title: Phase II Study of Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Malignant Mesothelioma
Study design: Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: To determine the response to the combination of bevacizumab and erlotinib in previously treated malignant mesothelioma
To determine the time to tumor progression
to determine the duration of response
to determine the median and overall survival of patients
to determine the safety of the drugs administered
Each cycle of study treatment lasts 21 days. The patient will take erlotinib by mouth once
daily. On day 1 of every cycle, the patient will receive bevacizumab intravenously over a
30-90 minute time period.
CT scan(s), MRI(s) and/or x-ray(s) of the cancer site will be performed every 6 weeks (2
cycles) to assess the extent of the response to treatment.
Bloodwork will be performed before the first dose of erlotinib and bevacizumab at Cycle 1,
Cycle 2, Cycle 3, and at the end of treatment.
At the completion of the treatment a physical exam, vital signs, blood tests, urine tests
and standard radiologic testing will be performed.
The duration of study depends upon how the patients' mesothelioma responds to treatment as
well as how well the patient tolerates the medication.
Minimum age: 18 Years.
Maximum age: N/A.
- Mesothelioma that has been previously treated with at least one chemotherapy regimen
- 18 years of age or older
- Must at least be able to walk and capable of taking care of oneself although unable
to carry out work activities
- Four or more weeks since last major surgery
- Four or more weeks since last radiation therapy
- Three or more weeks since last chemotherapy
- Life expectancy of 12 weeks or more
- Blood tests that show kidneys, liver and bone marrow to be working adequately
- Able to comply with study and/or follow-up procedures
- Prior exposure to Tarceva (OSI-774, erlotinib), trastuzumab, ZD1839 or C225
- Receiving anticoagulation medication other than low dose Coumadin
- Clinically significant heart disease such as uncontrolled hypertension, previous
heart attack within past 12 months, uneven heartbeat, etc.
- History of central nervous system disease such as seizures not controlled with
standard medical therapy, brain metastases or history of stroke
- Major surgery within 28 days of screening
- Daily treatment with aspirin or anti-inflammatory medications
- Pregnant or lactating (pertaining to women only)
- Serious or nonhealing wound, ulcer or bone fracture
- Difficulty swallowing
- A disease or disorder that interferes with ability to digest and absorb food
- History of coughing up more than 1/4 teaspoon of blood
- A medical condition that could make it unsafe for patient to participate in this
Locations and Contacts
The University of Chicago, Chicago, Illinois 60637, United States
Dana-Farber Cancer Institute, Boston, Massachusetts 02115, United States
Massachusetts General Hospital, Boston, Massachusetts 02114, United States
Dana-Farber Cancer Institute Lowe Thoracic Oncology Program
Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005 Jul 14;353(2):123-32.
Pérez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabárbara P, Bonomi P. Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. J Clin Oncol. 2004 Aug 15;22(16):3238-47.
Starting date: February 2004
Last updated: December 23, 2011